BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Increase in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 688,400 shares, an increase of 28.7% from the November 15th total of 534,800 shares. Based on an average daily volume of 5,250,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 15.42% of the company’s stock.

BriaCell Therapeutics Stock Performance

BCTX stock remained flat at $0.66 during mid-day trading on Friday. 2,234,086 shares of the company’s stock were exchanged, compared to its average volume of 1,642,969. The company’s fifty day moving average price is $0.84 and its 200 day moving average price is $0.89. The stock has a market cap of $23.88 million, a PE ratio of -0.56 and a beta of 1.46. BriaCell Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its earnings results on Monday, October 28th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.45. On average, research analysts forecast that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.